Vendor, Houston, TX
Auravax Therapeutics, Inc.
UEI PAN3ZK2YLAL2, CAGE 969E2
1 award and $749,999 obligated between September 16, 2024 and December 19, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $749,999 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $749,999 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00054Definitive Contract, September 16, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Overall Objective of This Contract Is to Assess the Ability of Auravax Therapeutics? (Auravax) Novel Mucosal Adjuvant Nanosting-002, TogNAICS 541714, PSC AN14 | $749,999 |
- Places of performance
- Texas
- Product and service codes
- AN14 Health R&D Services; Health Care Services; R&D Administrative Expenses
- Transactions
- 4 across 1 awards